Clostridioides difficile Infections (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2021, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape.Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridioides difficile Infections – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Clostridioides difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 11, 9, 38, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 7 molecules, respectively.Clostridioides difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridioides difficile Infections (Infectious Disease).- The pipeline guide reviews pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Clostridioides difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Clostridioides difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Clostridioides difficile Infections (Infectious Disease).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Clostridioides difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Acurx Pharmaceuticals LLC

Affinivax Inc

Appili Therapeutics Inc

Artugen Therapeutics Ltd

AzurRx BioPharma Inc

Biomica

Botanix Pharmaceuticals Ltd

Boulos and Cooper Pharmaceuticals Pty Ltd

Cambimune Ltd

Chain Biotechnology Ltd

Crestone Inc

CSA Biotechnologies LLC

Daiichi Sankyo Co Ltd

Deinove SAS

Destiny Pharma Plc

Enterobiotix Ltd

Facile Therapeutics Inc

Finch Therapeutics Group Inc

FloraSeq LLC

Fzata Inc

Galenus Therapeutics Inc

Gateway Pharmaceutical LLC

GlaxoSmithKline Plc

Immune Biosolutions Inc

ImmuneBiotech AB

ImmuniMed Inc

ImmunoBiology Ltd

Immuron Ltd

Inositec AG

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Integrated BioTherapeutics Inc

Kaleido Biosciences Inc

KamTek Inc

Kowa Co Ltd

Lumen Bioscience Inc

Mapp Biopharmaceutical Inc

Matrivax Research & Development Corp

MGB Biopharma Ltd

Microbiotica Ltd

Micropharm Ltd

Mikrobiomik Healthcare Company SL

MV BioTherapeutics SA

MyBiotics Pharma Ltd

Novabiotics Ltd

NovoBiotic Pharmaceuticals LLC

Nubiyota LLC

Oragenics Inc

Ostrich Pharma USA Inc

PanTheryx Inc

Pfizer Inc

Procarta Biosystems Ltd

Proxi Biotech IVS

Pylum Biosciences Inc

Q2 Pharma Ltd

QureTech Bio AB

Rebiotix Inc

Recursion Pharmaceuticals Inc

Rise Therapeutics LLC

Scioto Biosciences Inc

Seres Therapeutics Inc

Serometrix LLC

Servatus Ltd

Summit Therapeutics Ltd

Symbiotic Health Inc

Synterica Inc

Synthetic Biologics Inc

Takeda Pharmaceutical Co Ltd

TenNor Therapeutics Ltd

Valevia UK Ltd

Vedanta Biosciences Inc

Versatope Therapeutics Inc

Vitality Biopharma Inc

XBiotech Inc

Zhiyi Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Overview

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Acurx Pharmaceuticals LLC, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Affinivax Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Appili Therapeutics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Artugen Therapeutics Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by AzurRx BioPharma Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Biomica, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Botanix Pharmaceuticals Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Cambimune Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Chain Biotechnology Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Crestone Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by CSA Biotechnologies LLC, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Daiichi Sankyo Co Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Deinove SAS, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Destiny Pharma Plc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Enterobiotix Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Facile Therapeutics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Finch Therapeutics Group Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by FloraSeq LLC, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Fzata Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Galenus Therapeutics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Gateway Pharmaceutical LLC, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by GlaxoSmithKline Plc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Immune Biosolutions Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by ImmuneBiotech AB, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by ImmuniMed Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by ImmunoBiology Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Immuron Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Inositec AG, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Inovio Pharmaceuticals Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Inspyr Therapeutics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Integrated BioTherapeutics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Kaleido Biosciences Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by KamTek Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Kowa Co Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Lumen Bioscience Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Mapp Biopharmaceutical Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Matrivax Research & Development Corp, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by MGB Biopharma Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Microbiotica Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Micropharm Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Mikrobiomik Healthcare Company SL, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by MV BioTherapeutics SA, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by MyBiotics Pharma Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Novabiotics Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by NovoBiotic Pharmaceuticals LLC, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Nubiyota LLC, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Oragenics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Ostrich Pharma USA Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by PanTheryx Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Pfizer Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Procarta Biosystems Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Proxi Biotech IVS, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Pylum Biosciences Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Q2 Pharma Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by QureTech Bio AB, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Rebiotix Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Recursion Pharmaceuticals Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Rise Therapeutics LLC, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Scioto Biosciences Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Seres Therapeutics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Serometrix LLC, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Servatus Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Summit Therapeutics Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Symbiotic Health Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Synterica Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Synthetic Biologics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by TenNor Therapeutics Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Valevia UK Ltd, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Vedanta Biosciences Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Versatope Therapeutics Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Vitality Biopharma Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by XBiotech Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Zhiyi Pharmaceuticals Inc, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2021

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2021 (Contd..1)

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2021 (Contd..2)

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2021 (Contd..3)

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports